IPO round-up: Mainstay raises €18m; Union MedTech takes step closer to REX with £10m
This article was originally published in Clinica
Executive Summary
Irish orthopedic firm Mainstay Medical has raised €18m ($25m) in its initial public offering, slightly less than its €23m target. According to The Irish Times, the firm sold around 850,000 shares at €21.15 each, at the low end of the €20-27 range it had previously given. The IPO was a dual listing on the Irish Stock Exchange and the Paris Euronext market. Mainstay will use the funds to conduct clinical trials of its ReActiv8 treatment for chronic low back pain, initially in Australia and then in Europe, and to submit an application for CE mark approval. ReActiv8 is an implanted device that stimulates nerves responsible for contracting the key muscles that stabilize the lower back. Medtech giant Medtronic is one of Mainstay’s investors.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.